World Acceptance Corporation engages in small-loan consumer finance business. The company has market cap of $696.11 million. The firm offers short-term small and medium-term larger installment loans, as well as related credit insurance and ancillary services and products to individuals. It has a 10.9 P/E ratio. It also provides automobile club memberships to its borrowers; and income tax return preparation and electronic filing services.
Clearside BioMedical, Inc. (CLSD) formed H&S with $6.77 target or 4.00% below today’s $7.05 share price. Clearside BioMedical, Inc. (CLSD) has $178.66M valuation. The stock increased 19.69% or $1.16 during the last trading session, reaching $7.05. About 420,254 shares traded or 217.89% up from the average. Clearside BioMedical, Inc. (NASDAQ:CLSD) has 0.00% since December 12, 2016 and is . It has underperformed by 16.70% the S&P500.
Analysts await World Acceptance Corporation (NASDAQ:WRLD) to report earnings on January, 25. They expect $0.95 EPS, down 13.64% or $0.15 from last year’s $1.1 per share. WRLD’s profit will be $8.31 million for 20.94 P/E if the $0.95 EPS becomes a reality. After $1.10 actual EPS reported by World Acceptance Corporation for the previous quarter, Wall Street now forecasts -13.64% negative EPS growth.
The stock decreased 0.21% or $0.17 during the last trading session, reaching $79.56. About 42,018 shares traded. World Acceptance Corporation (WRLD) has risen 103.20% since December 12, 2016 and is uptrending. It has outperformed by 86.50% the S&P500.
Prescott General Partners Llc holds 8.19% of its portfolio in World Acceptance Corporation for 2.04 million shares. Smith Thomas W owns 93,950 shares or 6.21% of their US portfolio. Moreover, Nantahala Capital Management Llc has 2.64% invested in the company for 443,861 shares. The New York-based Indus Capital Partners Llc has invested 1.75% in the stock. Weber Alan W, a New York-based fund reported 26,069 shares.
Analysts await Clearside BioMedical, Inc. (NASDAQ:CLSD) to report earnings on March, 13. They expect $-0.65 earnings per share, down 44.44% or $0.20 from last year’s $-0.45 per share. After $-0.72 actual earnings per share reported by Clearside BioMedical, Inc. for the previous quarter, Wall Street now forecasts -9.72% EPS growth.
Among 4 analysts covering Clearside Biomedical (NASDAQ:CLSD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Clearside Biomedical had 5 analyst reports since June 27, 2016 according to SRatingsIntel. The stock of Clearside BioMedical, Inc. (NASDAQ:CLSD) has “Buy” rating given on Monday, October 24 by Stifel Nicolaus. The stock of Clearside BioMedical, Inc. (NASDAQ:CLSD) has “Buy” rating given on Tuesday, June 28 by Needham. The stock has “Buy” rating by Stifel Nicolaus on Monday, June 27. On Monday, June 27 the stock rating was initiated by Cowen & Co with “Outperform”. The stock of Clearside BioMedical, Inc. (NASDAQ:CLSD) earned “Outperform” rating by Wedbush on Monday, June 27.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.